EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSBTAG00000007882
Gene Symbol: CACNA1B
5 Cross references
301 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 C

Ensembl ID : ENSBTAG00000010660
Gene Symbol: CACNA1C
7 Enzyme and pathways 5 Cross references
223 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSBTAG00000010026
Gene Symbol: CACNA1D
3 Enzyme and pathways 5 Cross references
293 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSBTAG00000020887
Gene Symbol: CACNA1E
6 Enzyme and pathways 5 Cross references
306 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSBTAG00000016097
Gene Symbol: CACNA1F
5 Cross references
188 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSBTAG00000009835
Gene Symbol: CACNA1G
2 Enzyme and pathways 5 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 H

Ensembl ID : ENSBTAG00000026461
Gene Symbol: CACNA1H
5 Cross references
225 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSBTAG00000045610
Gene Symbol: CACNA1I
5 Cross references
207 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 S

Ensembl ID : ENSBTAG00000047491
Gene Symbol: CACNA1S
5 Cross references
278 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSBTAG00000054523
Gene Symbol: CNR1
6 Enzyme and pathways 5 Cross references
219 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSBTAG00000019371
Gene Symbol: CNR2
6 Enzyme and pathways 5 Cross references
208 Possible Orthologues:

Carbonic Anhydrase 1

Ensembl ID : ENSBTAG00000036116
Gene Symbol: LOC784254
4 Cross references
287 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).